EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

Addition of plerixafor in poorly mobilized allogeneic stem cell donors

Lefan Zhuang, Deisen Lauro, Shirong Wang, Shan Yuan

Journal of Clinical Apheresis · 2022-08 · 37 (4) · 388-394

DOI: 10.1002/jca.21992 ↗

At a glance

Journal article in Journal of Clinical Apheresis, published online on 2022-05-28. Written by Lefan Zhuang and 3 co-authors. Institution: Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA. Major MEDLINE topics: Cyclams, Hematopoietic Stem Cell Transplantation, Heterocyclic Compounds, Peripheral Blood Stem Cells. Cited 8 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Peripheral blood stem cells (PBSCs) are the predominant graft source for adult allogeneic hematopoietic stem cell transplantation (HSCT). In poorly mobilized autologous donors, plerixafor improves collection outcomes. We examine plerixafor use in allogeneic donors who mobilize poorly with granulocyte colony‐stimulating factor (G‐CSF) in those who are healthy and those with pre‐existing medical conditions, and determine the optimal threshold to add plerixafor. Study Design/Methods We retrospectively examined all allogeneic PBSC collections from January 2013 to October 2020 at our center. Donors received G‐CSF 10 mcg/kg daily for 4 days before undergoing apheresis collection on day 5. Plerixafor was added based on poor CD34+ cell collection yield after the first or second collection day.

Results

Of the 1008 allogeneic donors, 41 (4.1%) received one dose of plerixafor in addition to G‐CSF due to poor collection yield. After starting plerixafor there was a 0.75‐ to 7.74‐fold (median 2.94) increase in CD34+ yield from the previous day. No donors with G‐CSF‐only mobilization who collected

Subjects

MeSH terms (MEDLINE)

CyclamsHematopoietic Stem Cell TransplantationHeterocyclic CompoundsPeripheral Blood Stem CellsAdultAntigens, CD34BenzylaminesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansRetrospective Studies

Author keywords

plerixaforstem cell collection

Substances

Antigens, CD34BenzylaminesCyclamsHeterocyclic CompoundsGranulocyte Colony-Stimulating Factorplerixafor

Authors and institutions

  • Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.

Cite

APA

Zhuang, L., Lauro, D., Wang, S., & Yuan, S. (2022). Addition of plerixafor in poorly mobilized allogeneic stem cell donors. Journal of Clinical Apheresis, 37(4), 388-394. https://doi.org/10.1002/jca.21992

Vancouver

Zhuang L, Lauro D, Wang S, Yuan S. Addition of plerixafor in poorly mobilized allogeneic stem cell donors. Journal of Clinical Apheresis. 2022;37(4):388-394. doi:10.1002/jca.21992

BibTeX
@article{Zhuang2022,
  author = {Zhuang, Lefan and Lauro, Deisen and Wang, Shirong and Yuan, Shan},
  title = {Addition of plerixafor in poorly mobilized allogeneic stem cell donors},
  journal = {Journal of Clinical Apheresis},
  year = {2022},
  volume = {37},
  number = {4},
  pages = {388--394},
  doi = {10.1002/jca.21992}
}
Start for free →